STAAR Surgical (STAA) boosts interim co-CEO and CFO Deborah Andrews’ salary and bonus

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

STAAR Surgical Company updated the compensation of Deborah Andrews, its Interim Co-Chief Executive Officer and Chief Financial Officer. Effective June 8, 2026, her annual base salary increases from $512,000 to $575,000. Her target annual cash bonus also rises from 55% to 60% of base salary, reflecting a review of market data and her contributions to the company’s strategic and operational objectives.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Previous base salary: $512,000 per year New base salary: $575,000 per year Old target bonus: 55% of base salary +3 more

6 metrics

Previous base salary $512,000 per year Deborah Andrews’ base salary before June 8, 2026

New base salary $575,000 per year Deborah Andrews’ salary effective June 8, 2026

Old target bonus 55% of base salary Target annual cash bonus before the change

New target bonus 60% of base salary Target annual cash bonus effective June 8, 2026

Effective date June 8, 2026 Date compensation changes become effective

Form type 8-K Item 5.02 Disclosure of officer compensatory arrangements

Key Terms

Compensation Committee, target annual cash bonus, Interim Co-Chief Executive Officer, principal executive offices, +1 more

5 terms

Compensation Committee financial

"On June 8, 2026, the Compensation Committee (the “Committee”) of the Board of Directors..."

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

target annual cash bonus financial

"the Committee approved an increase in the target annual cash bonus for Ms. Andrews..."

Interim Co-Chief Executive Officer financial

"Deborah Andrews, the Company's Interim Co-Chief Executive Officer and Chief Financial Officer..."

principal executive offices financial

"25510 Commercentre Drive Lake Forest , California ... (Address of principal executive offices)"

Emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/09/2026 - 01:02 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 8, 2026

STAAR Surgical Company

(Exact name of registrant as specified in its charter)


Delaware	0-11634	95-3797439
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

25510 Commercentre Drive Lake Forest, California		92630
(Address of principal executive offices)		(Zip Code)

626-303-7902

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common	STAA	NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 8, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of STAAR Surgical Company (the “Company”) approved an increase to the annual base salary of Deborah Andrews, the Company's Interim Co-Chief Executive Officer and Chief Financial Officer from $512,000 to $575,000. In addition, the Committee approved an increase in the target annual cash bonus for Ms. Andrews from 55% to 60% of her base salary. Both the base salary increase and bonus increase are effective June 8, 2026.

The compensation adjustments were made following the Committee’s review of competitive market compensation data and in recognition of Ms. Andrew's contributions to the Company’s strategic and operational objectives.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STAAR SURGICAL COMPANY

By: /s/ Warren Foust

Name: Warren Foust

Title: Interim Co-Chief Executive Officer and Chief Operating Officer

Dated: June 9, 2026

Source: View Original Filing on SEC EDGAR

FAQ

What executive compensation change did STAAR Surgical (STAA) disclose?

STAAR Surgical increased compensation for Deborah Andrews, Interim Co-CEO and CFO. Her base salary rises to $575,000 and her target cash bonus increases to 60% of salary, reflecting market data and recognition of her contributions to strategic and operational objectives.

What is Deborah Andrews’ new base salary at STAAR Surgical (STAA)?

Deborah Andrews’ new annual base salary is $575,000. This is an increase from $512,000, approved by the Compensation Committee, and is effective June 8, 2026, for her role as Interim Co-Chief Executive Officer and Chief Financial Officer.

How did STAAR Surgical (STAA) change Deborah Andrews’ target bonus?

Her target annual cash bonus increased from 55% to 60% of base salary. This higher bonus opportunity applies starting June 8, 2026, and was approved after the Compensation Committee reviewed competitive market compensation data for comparable executive roles.

When do the compensation changes for Deborah Andrews at STAAR Surgical (STAA) take effect?

The compensation changes take effect on June 8, 2026. From that date, Deborah Andrews’ base salary is $575,000 and her bonus target is 60% of salary, covering her responsibilities as Interim Co-Chief Executive Officer and Chief Financial Officer.

Why did STAAR Surgical (STAA) raise Deborah Andrews’ pay?

The Compensation Committee increased her pay after reviewing competitive market compensation data. The filing also states the changes recognize Deborah Andrews’ contributions to STAAR Surgical’s strategic and operational objectives in her dual role as Interim Co-CEO and CFO.

Filing Exhibits & Attachments

1 document